News
-
-
-
-
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting
Tharimmune presents positive Phase 1 data for TH104 in treating pruritus in chronic liver disease patients at ACG 2024. No opioid withdrawal effects observed, supporting safety profile